Novo Nordisk AS (NVO)
102.05
-3.27
(-3.10%)
USD |
NYSE |
Nov 15, 12:14
Novo Nordisk Free Cash Flow (Quarterly): 4.748B for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.748B |
| June 30, 2024 | 5.372B |
| March 31, 2024 | 772.71M |
| December 31, 2023 | -1.065B |
| September 30, 2023 | 4.425B |
| June 30, 2023 | 3.197B |
| March 31, 2023 | 3.607B |
| December 31, 2022 | 534.67M |
| September 30, 2022 | 2.374B |
| June 30, 2022 | 2.894B |
| March 31, 2022 | 3.289B |
| December 31, 2021 | -817.54M |
| September 30, 2021 | 3.025B |
| June 30, 2021 | 3.787B |
| March 31, 2021 | 1.582B |
| December 31, 2020 | -2.116B |
| September 30, 2020 | 2.088B |
| June 30, 2020 | 3.381B |
| March 31, 2020 | 1.224B |
| December 31, 2019 | 361.95M |
| September 30, 2019 | 2.093B |
| June 30, 2019 | 1.833B |
| March 31, 2019 | 1.043B |
| December 31, 2018 | 614.42M |
| September 30, 2018 | 1.272B |
| Date | Value |
|---|---|
| June 30, 2018 | 2.084B |
| March 31, 2018 | 1.131B |
| December 31, 2017 | 253.41M |
| September 30, 2017 | 1.917B |
| June 30, 2017 | 1.292B |
| March 31, 2017 | 1.488B |
| December 31, 2016 | 1.205B |
| September 30, 2016 | 1.851B |
| June 30, 2016 | 1.959B |
| March 31, 2016 | 936.48M |
| December 31, 2015 | 1.029B |
| September 30, 2015 | 1.620B |
| June 30, 2015 | 1.593B |
| March 31, 2015 | 501.18M |
| December 31, 2014 | 1.039B |
| September 30, 2014 | 1.914B |
| June 30, 2014 | 1.330B |
| March 31, 2014 | 599.92M |
| December 31, 2013 | 810.97M |
| September 30, 2013 | 958.68M |
| June 30, 2013 | 1.109B |
| March 31, 2013 | 1.093B |
| December 31, 2012 | 151.91M |
| September 30, 2012 | 1.108B |
| June 30, 2012 | 1.064B |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-2.116B
Minimum
Dec 2020
5.372B
Maximum
Jun 2024
2.133B
Average
2.634B
Median
Free Cash Flow (Quarterly) Benchmarks
| Ascendis Pharma AS | -- |
| Amgen Inc | 3.314B |
| AstraZeneca PLC | 2.417B |
| Grifols SA | -- |
| Viking Therapeutics Inc | -21.96M |